Balanced news tone
News Sentiment
GNLX sentiment intelligence
Genelux Corporation Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-5.3% over one week, -3.2% over four weeks, trend inactive, and below fair value.
Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Genelux Corp (GNLX) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of Genelux Corp (GNLX) from TradingKey, noting a current financial score of 7.05, which ranks it 159 out of 388 in the Biotechnology & Medical Research industry. The company's financial status is described as stable, but its opera
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 06:41
- Source
- TradingKey
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- Market source
Genelux head of regulatory Ralph Smalling sells $562 in stock By Investing.com
Ralph Smalling, Head of Regulatory at GENELUX Corp, sold 192 shares of company stock worth $562 to cover taxes on restricted stock units. Following the sale, Smalling retains 67,611 shares, and the stock is currently trading at $3.08, significantly below its 52-week high. Investi
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 05 Jun 2026 14:40
- Source
- Investing.com India
Genelux head of regulatory Ralph Smalling sells $562 in stock
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 04 Jun 2026 07:00
- Source
- Investing.com
Genelux director Thomas John sold $29,801 in company stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Investing.com
UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+
- Tone
- Positive 84/100
- Event
- Earnings
- Published
- 26 May 2026 07:00
- Source
- eciks.org
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Genelux CSO Yu Yong sells $1,798 of common stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 May 2026 07:00
- Source
- Investing.com
Genelux president and CEO Zindrick Thomas sells $8,225 in stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 May 2026 07:00
- Source
- Investing.com
Genelux CTO Joseph Cappello sells $1,799 in company stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 May 2026 07:00
- Source
- Investing.com
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- GlobeNewswire
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- Market source
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Mar 2026 08:00
- Source
- Stocktwits
Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Feb 2026 09:53
- Source
- Kavout | AI
Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 26 Feb 2026 08:00
- Source
- TIKR.com
Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 25 Feb 2026 08:00
- Source
- TIKR.com
This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Feb 2026 08:00
- Source
- Barron's
Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 Feb 2026 08:00
- Source
- Barron's
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jan 2026 08:00
- Source
- GlobeNewswire
Genelux Corporation Announces Proposed Public Offering of Common Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jan 2026 08:00
- Source
- Market source
Genelux stock falls after announcing proposed public offering
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 07 Jan 2026 08:00
- Source
- Investing.com
Multiple Insiders Sold Genelux Shares Presenting Weak Signs For Investors
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 06 Jan 2026 08:00
- Source
- simplywall.st
Genelux: Oncolytic Virus Player Near Phase 3 Finish Line, But Correction Likely (GNLX)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Nov 2025 08:00
- Source
- Seeking Alpha
$GNLX stock is down 30% today. Here's what we see in our data.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Nov 2025 08:00
- Source
- Quiver Quantitative